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Abstract 
 
Background: Formal reference ranges for rotational thromboelastometry (ROTEM®) in pregnancy have not 
been obtained in the recommended minimum sample size of 120. This prospective observational study aimed to 
establish baseline parameters in an Australian population of women undergoing elective caesarean delivery. The 
secondary aim was to compare these reference ranges with those from prior studies and the manufacturer.  
 
Methods: Women undergoing elective caesarean delivery at term were included if they were at term, with 
normal body mass index and had no conditions affecting coagulation. ROTEM® reference ranges were derived 
by calculating the 2.5 and 97.5 percentiles for INTEM/EXTEM/FIBTEM amplitude at 5 minutes (A5), 
amplitude at 15 minutes (A15), coagulation time (CT), maximum clot firmness (MCF), and clot formation time 
(CFT). 
 
Results: Of 202 women screened, 132 met the inclusion criteria, having a mean age of 32.7 ± 5.0 years and 
median body mass index of 23.8 kg/m2 (interquartile range 21.5-26.4). The reference ranges for selected 
ROTEM® parameters were as follows: FIBTEM A5 (13-28 mm), FIBTEM CT (40-74 s), FIBTEM MCF (16-34 
mm), EXTEM A5 (39-66 mm), EXTEM CT (43-69 s), INTEM A5 (38-63 mm). 
 
Conclusions: ROTEM® reference ranges for women with uncomplicated term pregnancies were reported as 
per the International Federation of Clinical Chemistry. The FIBTEM MCF and FIBTEM/EXTEM/INTEM 
amplitudes were higher in comparison to the manufacturer’s reference ranges for the non-obstetric population. 
The EXTEM CT was shorter than the non-obstetric reference ranges. These ranges show an increase in 
coagulability during normal pregnancy compared to the non-pregnant reference ranges. 
 
 
Keywords: Coagulation; elective caesarean deliveries; pregnancy; reference ranges; rotational 
thromboelastometry; ROTEM®; third trimester. 
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Introduction 
 
Postpartum haemorrhage (PPH) remains the leading cause of maternal morbidity and mortality worldwide.1, 2 In 
pregnancy, there is a physiological shift towards hypercoagulation,3 despite compensatory mechanisms of 
haemodilution and an increase in tissue factor-pathway inhibitor (TFPI) activity.3 However, as placental blood 
flow at term constitutes 15 percent of the total cardiac output, obstetric haemorrhage can be a life threatening 
event.4 Rotational thromboelastometry (ROTEM®) is a point-of-care test of coagulation. ROTEM®-guided 
transfusion of blood products has consistently shown a significant reduction in bleeding and transfusion 
requirements in the trauma setting.5-7 Its use is well established in hepatic and cardiac surgery and it is being 
used increasingly in obstetric care.3, 8, 9   
Management of obstetric haemorrhage may be optimised by knowledge of ROTEM® reference ranges specific 
to the obstetric population, due to the hypercoagulable state in pregnancy.  However, there is a lack of 
standardisation and data for the definition of normal ROTEM® values and controls in obstetric care. Currently, 
reference ranges have been obtained from the non-pregnant population and are inferred in the pregnant 
population. Therefore, formal baseline parameters for ROTEM® need to be established in normal pregnancy, as 
per the International Federation of Clinical Chemistry (IFCC).  The IFCC recommends a minimum sample size 
of 120 for establishing reference ranges. One hundred and twenty observations are required to determine both 
the central 95% of the distribution, by calculating the 2.5th and 97.5th percentile, and the 90% confidence limits 
of both endpoints.10, 11 There are several studies published reporting reference ranges in obstetrics,12-16 but they 
report from samples of less than 120 women.12, 14, 15  
This prospective observational study aimed to establish baseline parameters in an Australian obstetric 
population undergoing elective caesarean delivery at term. A secondary aim was to compare the values with 
reference ranges available from prior studies and the manufacturer.17 
 
Methods 
 
This manuscript adheres to the STROBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) Statement. This single-centre observational study was conducted at a tertiary referral hospital 
with institutional review board approval (HREC/14/QRBW/496). Written informed participant consent was 
obtained.   
Women with singleton pregnancies were recruited from the maternity preadmission clinic if they were booked 
for an elective caesarean delivery at term (>37 weeks’ gestation); aged 18-45 years; of body mass index (BMI) 
of 18.5-30 kg/m2; and having an uncomplicated pregnancy. Women were excluded if they had pre-existing co-
morbidities, pregnancy-related conditions, or were taking medications affecting coagulation.  Excluded 
pregnancy-related conditions included the following: gestational hypertension, pre-eclampsia and HELLP 
(haemolysis, elevated liver enzymes and low platelet count) syndrome, as defined according to guidelines of the 
Society of Obstetric Medicine of Australia and New Zealand18); gestational diabetes mellitus, defined according 
to criteria of the  Queensland Clinical Guidelines19; and anaemia, defined according to the World Health 
Organisation definition.20 Women with the following conditions were also excluded: gestational 
thrombocytopaenia, cholestasis of pregnancy, antepartum haemorrhage, Factor V Leiden deficiency, 
antiphospholipid syndrome, haemochromatosis, thalassaemia and human immunodeficiency virus.  Women on 
anticoagulant drugs for thromboembolism or on aspirin were excluded.  
ROTEM® sampling occurred upon insertion of an intravenous cannula pre-operatively.  Blood samples were 
obtained by peripheral venepuncture and placed in standard 3.5 mL VacutainerTM collection tubes (Becton-
Dickinson, North Ryde, Australia) containing 3.2% sodium citrate.  The ROTEM® analysis occurred within two 
hours of specimen collection. The ROTEM® results were reviewed retrospectively and were not used to alter 
clinical management.  
All ROTEM® tests were performed by trained personnel, using citrated whole blood and a ROTEM® Delta 
analyser (Pentapharm, Munich, Germany). The INTEM, EXTEM and FIBTEM tests were performed on three 
parallel channels simultaneously, using automated pipette programmes according to the manufacturer’s 
instructions. The ROTEM® parameters of clotting time (CT), clot formation time (CFT), clot formation rate 
(CFR), alpha angle, maximum clot firmness (MCF), amplitude at five, 10, 15, 20 and 30 minutes (A5, A10, 
A15, A20, A30), the area under the curve (AUC) and the maximum velocity (MaxV) were calculated and 
compared to the manufacturer’s reference ranges for the non-obstetric population.  
A minimum sample size of 120 was targeted for establishing reference values, as per the IFCC 
recommendations.  This minimum number provides enough data to determine both the central 95% of the 
distribution and the 90% confidence limits of both endpoints.  With 120 observations, rank 3 is the 2.5th 
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percentile; rank 118 is the 97.5th percentile; ranks 1 and 7 define the 90% confidence interval of the 2.5th 
percentile; and ranks 114 and 120 define the 90% confidence interval of the 97.5th percentile.10  The ROTEM® 
reference ranges were derived by calculating the 2.5 and 97.5 percentiles, as well as stating the minimum and 
maximum values for INTEM/EXTEM/FIBTEM parameters, including A5, A15, CT, MCF and CFT.   Statistical 
analysis was performed using SPSS Statistics Software Version 23.  Categorical variables were summarised by 
frequencies and percentages; continuous variables by means and standard deviations; and median and 
interquartile range (IQR) for non-normally distributed variables. 
 
Results 
Two hundred and two women were screened between January and December 2016 and one hundred and thirty-
two (59%) met inclusion criteria.  Fig. 1 shows the reasons for exclusion. The women had a mean age of 32.7 ± 
5.0 years, a median gestation of 39 weeks (IQR 38.3-39.3), and median BMI of 23.8 kg/m2 (IQR 21.5-26.4). 
Twenty-six (19.7%) women were nulliparous and 89 (67.4%) were presenting for a repeat caesarean delivery 
(Table 1). The medians and IQRs for selected ROTEM® parameters are shown in Tables 2-4.  Table 5 shows 
information on the study cohort for this current study and prior studies. A comparison with reference limits from 
previous studies is shown in Table 6. 
 
Discussion 
This is the first study to establish baseline ROTEM® parameters with the minimum number of 120 women using 
three different assays (FIBTEM, EXTEM and INTEM), in a cohort of healthy pregnant women at term with 
singleton pregnancies and a normal BMI. The study provides more reference limits than all previously published 
studies combined. We observed results consistent with the hypercoagulable state in pregnancy. The FIBTEM 
MCF was higher in comparison to the manufacturer’s reference range for the non-obstetric population. 
Similarly, the EXTEM and INTEM MCF, were higher and narrower in range. The FIBTEM/EXTEM/INTEM 
amplitudes were also higher than the non-obstetric population. The EXTEM CT was shorter than the non-
obstetric reference range, with the upper and lower limits differing by more than 10 percent.  Narrower ranges 
were also demonstrated for EXTEM CFT, alpha angle, and INTEM CFT. 
The manufacturer’s reference ranges for the non-obstetric population are based on a study by Lang et al.17 This 
was a multicentre trial across six sites and included non-pregnant individuals, blood donors, clinical personnel, 
and cardiac patients.  
Several studies have confirmed a hypercoagulable state of pregnancy, in the form of a slightly shorter CT, and 
significantly greater clot firmness.12, 13, 21, 22 These studies were designed to define reference ranges, but were of 
inadequate sample size and applied different exclusion criteria. Armstrong et al.12 analysed 54 pregnant women 
and 54 non-pregnant women. Parturients had significantly lower haemoglobin values and platelet counts. 
Despite this, thromboelastometry exhibited significantly lower INTEM CT (7.3%), INTEM CFT (11.1%) and 
EXTEM CFT (18.0%) in the pregnant group.  The MCF values were significantly higher (INTEM 10.9%, 
EXTEM 10.6% and FIBTEM 47.1%) in the pregnant group compared to the non-pregnant group. However, 
they did not analyse ROTEM® values other than CT, CFT, alpha angle and MCF.12  The change in ROTEM® 
parameters has been shown to be gradual throughout the three trimesters with a significant increase in 
hypercoagulability by the second trimester and further increase in the final trimester.15 This was demonstrated 
by Bowden et al.15 in less than 100 women in each trimester and the control group.  
An increase in EXTEM and INTEM MCF with a shorter EXTEM CT was confirmed by Duraj et al.14 in the 
third trimester, in 57 non-obese healthy pregnant women with a BMI less than 30 kg/m2. The authors did not 
test for the FIBTEM values.14   
The only study to date that has met the IFCC sample size criterion for determining reference ranges is de Lange 
et al.13 However, this study was limited by the inclusion of both parturients and elective caesarean participants, 
and those of a gestation of less than 37 weeks. They also did not discriminate based on BMI and included twin 
pregnancies.  De Lange et al.13  provided values for A10 and A20, but not A5, which has greater clinical utility. 
Our reference ranges have been established in term pregnancies, but the results are not generalisable to other 
pregnant women such as those with obesity, gestational diabetes mellitus, coagulopathies, anaemia and those in 
established labour or at earlier gestations.   
The inclusion and exclusion criteria used in this study were similar to previous studies, but exclusion criteria 
were stricter. For example, prior studies included women with gestational diabetes mellitus, despite the 
tendency to develop thrombosis in this condition.23  Patients are at increased risk of bleeding when anaemic and 
studies have shown a hypercoagulable appearance in thromboelastography and ROTEM®.  One study analysed 
platelet function in anaemic blood and accelerated platelet aggregation was demonstrated at lower haemoglobin 
concentrations.24 
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The manufacturer recommends that each site should undergo a quality control process to generate their own 
normal ranges, as geography can have a significant influence on values. This process should also be repeated in 
the obstetric population at each institution to account for these changes.  Many institutions utilise viscoelastic 
testing and have established their own transfusion thresholds, based on the OBS2 trial results, rather than using 
obstetric-specific reference ranges.25 The OBS2 randomised controlled trial demonstrated that the infusion of 
fibrinogen concentrate triggered by a FIBTEM A5 value of less than 15 mm did not improve PPH outcomes.25 
However, a subgroup analysis suggest that fibrinogen is not required if the FIBTEM A5 is greater than 12 mm.25  
The reference ranges from this current study would not replace transfusion triggers, but complement their use in 
clinical practice. For example, an EXTEM clotting time value may appear normal if non-obstetric ranges were 
used, but may in fact be on the higher normal range or greater than the obstetric reference range. If a patient was 
still bleeding, then this knowledge would be useful in prompting the need for the transfusion of fresh frozen 
plasma. In contrast, if a FIBTEM A5 value appears normal based on non-obstetric ranges, the value may in fact 
be within the lower normal range or lower than the obstetric reference range. If the patient had ongoing blood 
loss, then this knowledge would be useful in prompting for the transfusion of fibrinogen. 
A limitation of the study is that ROTEM® was not repeated postpartum to investigate the rate and timing of 
normalisation of coagulation parameters to non-pregnant levels.  This would be of interest, as it has previously 
been shown that pregnancy-related hypercoagulability can persist for up to eight weeks postpartum.26  Another 
limitation is that this was performed within one institution from one geographic area. 
In conclusion, we have provided baseline reference ranges for ROTEM® values in women in our centre with 
uncomplicated pregnancies and who presented for an elective caesarean delivery at term. These ranges show an 
increase in coagulability during normal pregnancy compared to the non-pregnant population. Our study 
identified a difference in the obstetric population compared to the non-obstetric population and we  conclude 
that pregnancy-specific ROTEM® reference ranges should be used for obstetric care. 
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Fig. 1.  Recruitment flowchart detailing participant exclusions 
 
 
 
 
 
 
 
 
 
 
 
 
aPre-eclampsia and gestational hypertension as described in the SOMANZ Guidelines. Sourced from The 
SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy. 
https://www.somanz.org/documents/HTPregnancyGuidelineJuly2014.pdf (Accessed 01/818) 
bGestational diabetes mellitus as described in the guidelines from the Queensland Clinical Guidelines. Sourced 
from The Maternity and Neonatal Clinical Guideline: Gestational diabetes mellitus, published by Queensland 
Health, Australia. 2015. URL:// https://www.health.qld.gov.au/__data/assets/pdf_file/0023/140099/g-gdm.pdf 
Accessed August 1, 2018) 
 
 
  
202 elective caesarean 
delivery patients screened
Excluded based on Coagulopathy: 
Factor V Leiden deficiency (n=3) 
Anticoagulated (n=3)
Antiphospholipid syndrome (n=1)
Human Immunodeficiency Virus (n=1)
Haemochromatosis (n=1)
Thalassaemia alpha (n=2)
Excluded based on pregnancy complication:
Gestational thrombocytopaenia (n=2)
Pre-eclampsiaa (n=2)
Gestational diabetes mellitusb (n=12)
Anaemia (n=5)
Gestational hypertensiona (n=5)
Antepartum haemorrhage (n=2)
Cholestasis of pregnancy (n=1) 
Excluded due to sampling issues: 
Specimens clotted (n=2)
Excluded due to multiple gestation:
Twin pregnancies (n=4)
Receiving aspirin (n=2)
Excluded:
BMI ≥30kg/m2 (n=22)
Enrolled (n=132)
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Table 1. Demographic information of 132 women undergoing elective caesarean delivery at The 
Royal Brisbane and Women’s Hospital 
 
Characteristics (n=132) Total n (%) 
Indication for caesarean delivery     
    Repeat caesarean 
    Other  
 89 (67.4) 
43 (32.6) 
Nulliparous 26 (19.7) 
PPH 
   No 
   Yes 
 121 (91.7) 
11 (8.3) 
Maternal age (y), mean (SD)  32.7 (5.0) 
BMI (kg/m2), median (IQR) 23.8 (21.5-26.4) 
Gestation (weeks), median (IQR)            39.0 (38.6-39.3) 
PPH: postpartum haemorrhage. SD: standard deviation. BMI: body mass index. IQR: interquartile 
range. 
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Table 2. Reference ranges for FIBTEM parameters established using results from 132 women 
delivering by elective caesarean delivery at The Royal Brisbane and Women’s Hospital 
ROTEM® reference ranges were derived by calculating the 2.5 and 97.5 percentiles 
CT: clotting time. CFR: clot formation rate. MCF: maximum clot firmness. A5: amplitude (firmness) at 
5 minutes. A10: amplitude at 10 minutes. A15: amplitude at 15 minutes. A20: amplitude at 20 
minutes. A30: amplitude at 30 minutes. AUC: area under curve. MaxV: maximum velocity. IQR: 
interquartile range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter n Min-Max Median (IQR) 
Reference 
range 
Manufacturer’s 
reference range 
CT 132 33-75 53 (48-58) 40-74 38-62 
CFR 131 67-85 77 (74-79) 67-82 - 
Alpha angle 131 58-81 76 (74-78) 67-81 - 
MCF 132 13-43 24 (21-27) 16-34 9-25 
A5 132 10-34 20 (17-22) 13-28 6-22 
A10 132 12-39 22 (19-24) 14-30 7-23 
A15 130 13-41 23 (20-25) 15-32 - 
A20 127 13-43 23 (20-26) 16-33 8-24 
A30 124 14-43 24 (21-27) 16-34 - 
AUC 132 1311-4314 2379 (2086-2639) 1634-3366 - 
MaxV 132 6-47 17 (14-20) 9-27 - 
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Table 3. Reference ranges for EXTEM parameters established using results from 132 women 
delivering by elective caesarean delivery at The Royal Brisbane and Women’s Hospital 
 
Parameter n    Min-Max Median (IQR) 
   Reference 
range 
Manufacturer’s 
reference range 
CT 132 42-78 54 (49-57) 43-69 38-79 
CFT 132 39-140 64 (57-71) 43-108 34-159 
CFR 132 71-83 79 (77-80) 71-82 - 
Alpha angle 132 67-82 77 (76-79) 69-82 63-83 
MCF 132 55-80 70 (68-73) 60-78 50-72 
A5 132 32-68 53 (50-57) 39-66 - 
A10 132 43-75 63 (61-67) 50-73 43-65 
A15 129 48-78 67 (65-70) 55-76 48-69 
A20 127 51-80 69 (67-72) 57-77 50-71 
A30 123 54-80 70 (68-73) 60-78 - 
AUC 132 5441-7928 6964 (6766-7234) 5960-7645 - 
MaxV 132 11-31 20 (18-22) 12-30 - 
ROTEM® reference ranges were derived by calculating the 2.5 and 97.5 percentiles 
CT: clotting time. CFR: clot formation rate. MCF: maximum clot firmness. A5: amplitude (firmness) at 
5 minutes. A10: amplitude at 10 minutes. A15: amplitude at 15 minutes. A20: amplitude at 20 
minutes. A30: amplitude at 30 minutes. AUC: area under curve. MaxV: maximum velocity. IQR: 
interquartile range. 
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Table 4. Reference ranges for INTEM parameters established using results from 132 women 
delivering by elective caesarean delivery at The Royal Brisbane and Women’s Hospital 
 
Parameter n Min-Max Median (IQR) Reference range 
Manufacturer’s 
reference range 
CT 132 108-270 165 (145-185) 115-245 100-240 
CFT 132 38-140 63 (53-71) 42-103 30-110 
CFR 132 70-83 78 (77-80) 71-83 - 
Alpha angle 132 69-82 77 (76-79) 70-82 70-83 
MCF 132 54-79 69 (66-71) 59-76 50-72 
A5 132 31-66 51 (48-55) 38-63 38-57 
A10 132 42-74 62 (59-65) 49-70 44-66 
A15 127 47-77 66 (63-69) 54-74 48-69 
A20 127 50-78 68 (65-70) 57-75 50-71 
A30 122 53-79 69 (66-71) 59-76 - 
AUC 132 5375-7820 6858 (6588-7069) 5886-7524 - 
MaxV 132 11-34 19 (17-23) 12-31 - 
ROTEM® reference ranges were derived by calculating the 2.5 and 97.5 percentiles 
CT: clotting time. CFR: clot formation rate. MCF: maximum clot firmness. A5: amplitude (firmness) at 
5 minutes. A10: amplitude at 10 minutes. A15: amplitude at 15 minutes. A20: amplitude at 20 
minutes. A30: amplitude at 30 minutes. AUC: area under curve. MaxV: maximum velocity. IQR: 
interquartile range. 
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Table 5. Study cohort information for all prior studies 
Study Our Study Lang et al. 
(2005)17 
(non-
obstetric 
ranges)  
Armstrong et 
al. (2011)12 
Bowden et 
al. 
(2016)15 
Duraj et al. 
(2015)14 
De Lange et al. 
(2014)13 
Huissoud et 
al. 
(2009)21 
Study size n=132 n=155 
INTEM 
n=202 
EXTEM 
n=143 
FIBTEM 
n=108 n=316 n=112 n=161 n=104 
Number of 
centres 
Single centre Multicentre 
(6 sites, 40-
60 from 
each site) 
Single centre Single centre Single centre Multicentre Single centre 
Study 
group 
Elective 
caesarean 
deliveries 
Non-
pregnant, 
blood 
donors, 
clinical 
personnel, 
heart 
patients 
(including 
patients 
with 
diabetes 
and renal 
insufficienc
y)  
n=54 
pregnant 
(elective 
caesarean 
delivery) 
n=54 non-
pregnant 
n=99 First 
trimester 
n=60 Second 
trimester 
n=80 Third 
trimester 
n=75 non-
pregnant 
n=55 Non-
pregnant 
n=57 Healthy 
pregnant 
women (n=50 
tested four 
times 
throughout 
pregnancy) 
Parturients 
(induced and 
spontaneous) 
and elective 
caesarean 
deliveries 
(elective and 
emergency) 
n=20 non-
pregnant 
n=17 First 
trimester 
n=9 Second 
trimester 
n=58 Third 
trimester 
Geographic
al location 
Australia Germany, 
France, 
Austria 
United 
Kingdom 
United 
Kingdom 
Slovakia The 
Netherlands 
France 
Ethnicities 75.8% Caucasian, 
9.1% South East 
Asian, 6.8% 
Indian, 7.6% 
Other, 0.8% 
Indigenous 
Australian 
- 79.6% 
Caucasian, 
7.4% Afro-
Caribbean, 
13% Asian 
- - 94.4% 
Caucasian, 
0.6% 
Indian/Pakista
ni, 0.6% 
African, 1.2% 
Mediterranean
, 1.2% South 
American, 
3.7% Other 
- 
Age 
exclusions 
<18 y 
>45 y 
- <18 y 
>45 y 
- <18 y 
>45 years 
- - 
Age (y) 32.7 (5.0) 45.4 (17.6) 
INTEM 
43.1 (15.9) 
EXTEM 
38.8 (14.1) 
FIBTEM 
33.5 (5.7) - - 31.6 [22-43] 29 [26-33] 
pregnant 
group 
30 [21-32] 
control group 
Weight 
exclusions 
BMI <18.5 or >30 
kg/m2 
- <50 kg 
>100 kg 
- BMI >30 kg/m2 - - 
BMI 23.8 [21.5-26.4] - - - - 24.6 [16.8-
41.5] 
- 
Gestational 
age 
(weeks) 
>37 weeks 
included only 
- - - - >24 weeks 
included 
- 
Past 
medical 
history 
exclusions 
Personal or 
family history of 
coagulation 
disorders 
Pregnancy 
and 
lactation 
Personal or 
family history 
of 
coagulation 
disorders 
Coagulopathi
es or 
conditions 
associated 
with 
Haemostasis 
defects  
Thromboembo
lic disease 
Twin 
pregnancies 
included 
Known 
bleeding 
Hypertension 
Inflammatory 
syndrome 
Chronic 
disease 
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Data are mean (SD) and median [IQR]. BMI: body mass index. HELLP: haemolysis, elevated liver enzymes, low platelets. GDM: 
gestational diabetes mellitus. APH: antepartum haemorrhage. HIV: human immunodeficiency virus. FBC: full blood count.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
coagulopathy disorders Coagulopathy 
Other 
exclusions 
Gestational 
hypertension 
Pre-eclampsia 
HELLP syndrome 
GDM 
Anaemia 
Gestational 
thrombocytopae
nia 
Cholestasis 
APH 
HIV 
Recent 
blood 
transfusion, 
recent 
surgery, 
raised liver 
enzymes 
Blood 
transfusion or 
surgery 
within 28 
days 
Abnormal FBC 
Smoking 
history or 
concurrent 
disease 
(cardiovascul
ar, renal, 
malignancy, 
liver disease) 
- Pre-eclampsia 
Fetal loss 
Preterm 
delivery 
Inadequate 
blood sampling 
- - 
Medication 
exclusions 
Medications 
affecting 
coagulation 
Antiplatelet 
medication, 
analgesics 
Medications 
affecting 
coagulation 
Medications 
affecting 
coagulation 
Anticoagulatio
n 
Antiplatelet 
Prophylactic or 
therapeutic 
coagulation 
Anticoagulati
on 
Antiplatelet 
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Table 6 Comparison of reference limits from previous studies 
 
Study Our Study 
Lang et al. 
(2005)17 
(non-obstetric) 
Armstrong et 
al. (2011)12 
Bowden 
et al. 
(2016)15 
Duraj et al. 
(2015)14 
De Lange et 
al. 
(2014)13 
Huissoud et 
al. 
(2009)21 
FIBTEM Parameters 
CT 53 (40-74) 51 (43-69) 49 (20-95) - - 39 (31-79) 5 [46-65] 
CFR 77 (67-82) - - - - - - 
Alpha angle 76 (67-81) - 78 (33-86) - - 79 (50-83) - 
MCF 24 (16-34) 16 (9-25) 25 (15-38) 23 (8-49) - 25 (22-28) 19 [17-23] 
A5 20 (13-28)  - 18 (7-31) - - 16[15-20] 
A10 22 (14-30) 14 (9-24) - - - 22 (12-38) - 
A15 23 (15-32) - - - - - 19 [17-22] 
A20 23 (16-33) 15 (8-21) - - - 24 (13-40) - 
A30 24 (16-34) - - - - - - 
AUC 2379 (1634-
3366) 
- - - - - - 
MaxV 17 (9-27) - - - - - - 
EXTEM Parameters 
CT 54 (43-69) 55 (42-74) 47 (31-80) - 42 [39-45] 45 (41-50) 53 [47-62] 
CFT 64 (43-108) 95 (46-148) 50 (34-86) - - 69 (62-81) 74 [66-89] 
CFR 79 (71-82) - - - - - - 
Alpha angle 77 (69-82) 72 (63-81) 80 (64-83) - - 77 (67-83) - 
MCF 70 (60-78) 60 (49-71) 73 (66-92) - 71 [69-73] 71 (42-78) 67 [64-71] 
A5 53 (39-66) - - - - - 49 [47-54] 
A10 63 (50-73) 53 (43-65) - - - 64 (61-68) - 
A15 67 (55-76) - - - - - 64 [62-68] 
A20 69 (57-77) 59 (50-69) - - - 70 (68-73) - 
A30 70 (60-78) 59 (50-69) - - -  - 
AUC 
6964 (5960-
7645) - 
- - -  - 
MaxV 20 (12-30) - - - -  - 
INTEM Parameters 
CT 165 (115-245) 184 (137-246) 140 (86-168) - 156 [142-180] 147 (109-225) 155 [132-186] 
CFT 63 (42-103) 63 (40-100) 48 (33-108) - - 55 (40-103) 66 [58-78] 
CFR 78 (71-83) - - - - - - 
Alpha angle 77 (70-82) 77 (71-82) 81 (71-83) - - 79 (70-82) - 
MCF 69 (59-76) 61 (52-72) 71 (55-79) - 71 [68-72] 71 (63-78) 66 [63-69] 
A5 51 (38-63) - - - - - 48 [45-52] 
A10 62 (49-70) 55 (44-68) - - - 64(55-72) - 
A15 66 (54-74) 48-69 - - - - 62 [60-66] 
A20 68 (57-75) 60 (50-71) - - - 70 (62-77) - 
A30 69 (59-76) 60 (51-72) - - - - - 
AUC 6858 (5886- - - -  - - 
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7524) 
MaxV 19 (12-31) - - - - - - 
Data are median and 2.5-97.5 percentiles except for column 5* and 7* which displays median [IQR].  CT: clotting time. CFR: clot 
formation rate. MCF: maximum clot firmness. A5: amplitude (firmness) at 5 minutes. A10: amplitude at 10 minutes. A15: amplitude at 
15 minutes. A20: amplitude at 20 minutes. A30: amplitude at 30 minutes. AUC: area under curve. MaxV: maximum velocity. IQR: 
interquartile range. 
 
 
 
 
 
 
 
 
 
HIGHLIGHTS  
 
 Rotational thromboelastometry reference ranges were established in term pregnancies 
 Measures of clot firmness were higher than non-obstetric reference ranges 
 Times to clotting onset were shorter than non-obstetric reference ranges 
 ROTEM® reference ranges in pregnant women were different to non-obstetric values 
 
 
